Fig. 4

Combination of Roblitinib and CPI-169 elicits robust anti-cancer effects in vivo. A-C Subcutaneous xenograft tumors established from SMMC-7721 cells were treated with vehicle or the indicated drugs. Shown are the tumors (A), tumor weight (B) and the tumor volume (C) from the recipient mice. Mice with SMMC-7721 xenografts were treated with vehicle (n = 6), CPI-169 (n = 6), Roblitinib (n = 6) or CPI-169 + Roblitinib (n = 6) for 2 weeks. Scale bars: 1 cm. Values are presented as mean ± SEM; One-way ANOVA with Tukey’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. D Representative H&E and IHC staining for H3K27me3, phospho-FGFR4 (p-FGFR4), Ki67 and Cleaved caspase-3 (cl. Caspase 3) in tumors. Scale bars: 50 μm. The intensity of Ki67 and Cleaved caspase-3 staining cells were quantified. Values are presented mean ± SEM; One-way ANOVA with Tukey’s multiple comparisons test, ***p < 0.001, ****p < 0.0001